http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 06:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html si-local-file:///var/storage/secattach/20260615/26643764.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html Mon, 15 Jun 2026 06:10:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html si-local-file:///var/storage/secattach/20260615/26643764.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html Mon, 15 Jun 2026 06:10:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html si-local-file:///var/storage/secattach/20260615/26643764.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+13/26643764.html Mon, 15 Jun 2026 06:10:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html si-local-file:///var/storage/secattach/20260610/26628584.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html Wed, 10 Jun 2026 11:28:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html si-local-file:///var/storage/secattach/20260610/26628584.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html Wed, 10 Jun 2026 11:28:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html si-local-file:///var/storage/secattach/20260610/26628584.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+10/26628584.html Wed, 10 Jun 2026 11:28:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html si-local-file:///var/storage/secattach/20260605/26609794.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html Fri, 05 Jun 2026 11:58:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html si-local-file:///var/storage/secattach/20260605/26609794.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html Fri, 05 Jun 2026 11:58:00 -0400 500124 O.00653232 RDY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html si-local-file:///var/storage/secattach/20260605/26609794.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++DR+REDDYS+LABORATORIES++++For%3A+Jun+05/26609794.html Fri, 05 Jun 2026 11:58:00 -0400 500124 O.00653232 RDY